Pre-operative strategies on clopidogrel use in coronary artery bypass grafting

Br J Cardiol (Acute Interv Cardiol) 2003;10:AIC 49–AIC 51 Leave a comment
Click any image to enlarge
Authors:

There is a lack of standards pertaining to stopping antiplatelet agents in patients with acute coronary syndromes prior to coronary surgery. We conducted a national survey of all centres performing cardiac surgery in the UK and Ireland into practices and standards in relation to clopidogrel and aspirin before coronary artery surgery (n=36).
The response rate was 89%. The majority of centres used combination antiplatelet therapy in either some or all pre-operative acute coronary syndrome patients (79%). Aspirin alone is given in 19% of this surgical subpopulation. Aspirin is stopped 4.9 + 0.5 days (mean + SEM) and clopidogrel 6.5 + 0.5 days prior to surgery. There are no clear departmental policies in most cases (21 of 32 units) regarding cessation of clopidogrel. A subjective increase in bleeding was reported in 69% of centres; in 15 centres (47%) patients had returned to theatre for bleeding.
Many units in the UK still do not have a policy regarding antiplatelet therapy in those patients with acute coronary syndromes who are awaiting coronary bypass surgery. A randomised controlled trial is probably the correct way of evaluating the best strategy on use and omission of aspirin and clopidogrel in this setting.








Advertisement

For UK healthcare professionals only


THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT